TG TherapeuticsTGTX
TGTX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
53% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 55
22% more capital invested
Capital invested by funds: $2.38B [Q3] → $2.91B (+$531M) [Q4]
22% more call options, than puts
Call options by funds: $137M | Put options by funds: $113M
7% more funds holding
Funds holding: 303 [Q3] → 325 (+22) [Q4]
2% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 95
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
3.6% less ownership
Funds ownership: 65.8% [Q3] → 62.19% (-3.6%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$55
45%
upside
Avg. target
$55
45%
upside
High target
$55
45%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Edward White 27% 1-year accuracy 40 / 149 met price target | 45%upside $55 | Buy Reiterated | 4 Mar 2025 |
Financial journalist opinion
Based on 15 articles about TGTX published over the past 30 days
Positive
Investors Business Daily
1 week ago
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles
Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.
Positive
Benzinga
1 week ago
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
Trading is subdued with TG Therapeutics, Inc. TGTX on Friday. But the shares remain in an uptrend and there is a good chance the trend will continue.
Positive
Zacks Investment Research
2 weeks ago
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?
TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Positive
Seeking Alpha
2 weeks ago
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer and autoimmune disorders. TG Therapeutics' BRIUMVI achieved significant sales growth in 2024, supporting positive cash flow and funding for future developments, including azer-cel for autoimmune disorders. DTIL is rated a speculative "Buy" due to its undervaluation, promising pipeline, and strategic partnerships, while TGTX is rated "Hold" due to its full valuation.
Positive
Seeking Alpha
2 weeks ago
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends. Upcoming pivotal trials and potential label updates for Briumvi, including subcutaneous administration, could enhance patient convenience and treatment efficacy.
Positive
Seeking Alpha
2 weeks ago
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include a shorter infusion time, lower malignancy risks, and a more favorable price compared to Ocrevus. TGTX's financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway.
Neutral
Investors Business Daily
3 weeks ago
Biotech Stock TG Therapeutics Hits A High In Market Meltdown
Biotech stock TG Therapeutics is outperforming the major indexes in a declining stock market. TGTX stock hit a new high on Friday.
Neutral
Investors Business Daily
3 weeks ago
S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout
These watch list stocks have beenholding near buy points while the market has been breaking down. The post S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout appeared first on Investor's Business Daily.
Positive
The Motley Fool
3 weeks ago
Why TG Therapeutics Stock Was Soaring This Week
Following news of an estimates-topping fourth quarter, TG Therapeutics (TGTX 9.24%) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date.
Neutral
GlobeNewsWire
3 weeks ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below.
Charts implemented using Lightweight Charts™